← All Clearside Biomedical, INC filings

Clearside Biomedical, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
CLSD
Clearside Biomedical, INC
SCHEDULE 13G: Stephen Boyd Wiles Discloses 5.2% Passive Stake in Clearside Biomedical, Inc.
Stephen Boyd Wiles has reported a beneficial ownership of 5.2% of Clearside Biomedical, Inc.'s common stock as of March 31, 2025, indicating a significant passive investment.
NASDAQ
CLSD
Clearside Biomedical, INC
SCHEDULE 13G/A: Major Investor Group Discloses 8.6% Stake in Clearside Biomedical
A group led by Bradford T. Whitmore has disclosed a combined beneficial ownership of 8.6% of Clearside Biomedical, Inc.'s common stock as of December 31, 2024.